New combo aims to outsmart Drug-Resistant leukemia

NCT ID NCT03513562

Ongoing Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding venetoclax to ibrutinib can eliminate resistance mutations in people with chronic lymphocytic leukemia (CLL) who have developed resistance to ibrutinib alone. The study enrolls 28 participants who are already taking ibrutinib and have a known resistance mutation. The goal is to see if the combination can make the cancer mutation-free after 12 treatment cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and ibrutinib
What this could lead to: If successful, this combination could help CLL patients overcome resistance to ibrutinib, potentially leading to longer remission without the need for stronger treatments.
What could go wrong: This is a small, early-phase study with only 28 participants, so results may not apply to all patients. The combination may cause side effects or fail to clear mutations in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA IBRUTINIB RESISTANCE

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.